Clinical presentations and pathophysiological mechanisms of dystroglycanopathy: advancing therapeutic strategies

Ameya S Walimbe1, Francesco Muntoni2, Kevin P Campbell3

  • 1Division of Pediatric Neurology and Developmental Neuroscience, Department of Pediatrics, Baylor College of Medicine, Houston, TX, USA.

The Lancet. Neurology
|June 17, 2026
PubMed

Insights

Dystroglycanopathies, a group of muscular dystrophies, stem from impaired α-dystroglycan function. Emerging therapies like gene therapy offer new hope for treating these complex genetic muscle disorders.

Area of Science:

  • Biochemistry
  • Genetics
  • Neurology

Background:

  • Dystroglycanopathies are a class of muscular dystrophies characterized by loss of function in the α-dystroglycan receptor.
  • This receptor is crucial for muscle and non-muscle tissue integrity.
  • Clinical presentations vary widely, from congenital forms to adult limb-girdle muscular dystrophy, often involving severe systemic complications.

Purpose of the Study:

  • To review the pathophysiology and genetic underpinnings of dystroglycanopathies.
  • To highlight current symptomatic management strategies.
  • To explore emerging therapeutic targets and clinical trial advancements.

Main Methods:

  • Literature review of pathophysiology and genetics.
  • Analysis of current clinical management approaches.
  • Survey of ongoing clinical trials for novel therapies.

Main Results:

  • Loss of α-dystroglycan function leads to diverse clinical phenotypes, including muscle weakness, cardiac issues, and CNS/ocular malformations.
  • Current treatments are primarily symptomatic.
  • New therapeutic avenues, including gene therapy and ribitol-based treatments, are under investigation.

Conclusions:

  • Understanding dystroglycanopathy mechanisms has identified promising therapeutic targets.
  • Gene therapy and other novel approaches show potential to improve treatment options for patients.
  • Further research and clinical trials are essential to translate these findings into effective clinical practice.

Related Concept Videos

Satellite Stem Cells and Muscular Dystrophy01:21

Satellite Stem Cells and Muscular Dystrophy

Satellite stem cells or myosatellite cells are quiescent stem cells that Alexander Mauro first identified in 1961. These cells are located between the sarcolemma, the plasma membrane of muscle fibers, and the basal lamina, the connective tissue sheath covering it. These mononucleated cells are activated in response to muscle injury, can transform into myoblasts, and may form or repair muscle fibers. Myosatellite cells can provide additional myonuclei for muscle regeneration or return to a...
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
Lysosomal Hydrolases01:22

Lysosomal Hydrolases

Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
Proteoglycans01:05

Proteoglycans

Glycans, a class of complex heterogeneous molecules, can be covalently attached to proteins to form glycosylated proteins that regulate various physiological and pathological processes. Glycosylated proteins or glycoproteins comprise N-linked and O-linked oligosaccharides. O-glycosylation is the most common type of protein glycosylation. Here, glycans attach to the oxygen atom of the hydroxyl groups of Serine or Threonine residues. O-linked glycosylation occurs later in protein processing,...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...